Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

AGM Statement

23 Oct 2008 14:25

RNS Number : 5547G
Marchpole Holdings PLC
23 October 2008
 



23 October 2008

Marchpole Holdings plc

("Marchpole" or "the Company")

Annual General Meeting Statement

At Marchpole Holdings Annual General Meeting held this morning the Chairman of Marchpole Holdings plc, Christopher Phillips, gave the following statement and update on current trading.

"At the time of the announcement on 5 August 2008 of our results for the 53 weeks ended 5 April 2008 we reported that the year to date had proved to be challenging, with very difficult trading conditions leading to a substantial loss for the full year. However, it has also been a year of significant change and some progress for the Group, as we continue to evolve into a diversified international luxury brand management business with a globally recognised portfolio of fashion brands.

Most recently we announced a successful fund raising of £2.5 million with Atlas Design, which provides the Company with a more secure foundation from which to pursue growth opportunities as they arise. In addition we have also appointed Atlas Chairman Peter Wahlberg and Atlas CEO Allan Ladow to the Board of Marchpole as non-executive directors, and we look forward to benefiting from the additional experience that they bring to the Company.

Significantly during the current financial period we have entered into a joint venture and licensing agreement with the DKNY menswear label, under the terms of which Marchpole will source, design, produce and distribute a full range of DKNY menswear apparel throughout the world, excluding the Indian and Japanese markets. The agreement is for an initial period of seven years, with the option to extend the licence for a further seven years.

Trading conditions in the current financial year continue to be extremely difficult as a result of the deterioration in consumer markets, following the ongoing global financial crisis. 

The Board is taking all appropriate measures to deal with the current challenging economic environment and is maintaining a regular dialogue with the Company's bankers, in common with most other businesses exposed to the retail sector. In the current environment the directors continue to review all options and will provide an update on the trading performance with the interim statement in early December."

For further information please contact:

For further information, please contact :

Bell Pottinger Corporate & Financial 020 7861 3232

David Rydell / Emma Kent

Marchpole Holdings plc 020 7908 7777

Chris Phillips, Chairman

Michael MorrisExecutive Deputy Chairman 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUOUORWRRRUAA
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.